• Map View
  • Street View
  • Directions
Enquire Now

Stallergenes Pharma

  • Posted on
  • 391

As of 2003, the company has started an ambitious clinical development program which consists of developing a new generation of allergen immunotherapy products: pharmaceutical specialties covering allergens that trigger 80% of respiratory allergies worldwide.

Stallergenes Greer is also exploring the possibilities to extend allergy immunotherapy use to other allergic diseases than just respiratory allergies. Notably through collaborations, Stallergenes Greer is continuing to invest to make AIT treatments accessible to more allergy patients through even less invasive routes and facilitating access to allergen immunotherapy for other impacting allergic diseases such as food allergies.